Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 29, 2024
Quantitative Systems Toxicology Modeling Informed Safe Dose Selection of Emvododstat in Acute Myeloid Leukemia Patients.
Journal: Clinical pharmacology and therapeutics
Published: August 21, 2023
Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia.
Journal: Frontiers in oncology
Published: December 10, 2021
Pharmacokinetics and Safety of PTC596, a Novel Tubulin-Binding Agent, in Subjects With Advanced Solid Tumors.
Journal: Clinical pharmacology in drug development
Published: October 06, 2020
Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent.
Journal: Molecular cancer therapeutics
Published: September 06, 2020
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: December 19, 2016
Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress-Regulated Protein Translation.
Journal: Clinical pharmacology in drug development
Published: July 11, 2015
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: May 20, 2014
Ataluren treatment of patients with nonsense mutation dystrophinopathy.
Journal: Muscle & nerve
Published: February 10, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026